Tau and Alzheimer's disease: Past, present and future
Cytoskeleton · 2024
DOI: 10.1002/cm.21822 ↗At a glance
Übersichtsarbeit in Cytoskeleton, 2024. Written by Khalid Iqbal. Institution: Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, New York,…. Major MEDLINE topics: Alzheimer Disease, Tauopathies. Cited 32 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIA NIH HHS, National Institutes of Health, Office for People With Developmental Disabilities.
Topics: Demenz
Abstract (original language)
My journey with tau started when in 1974 for the first time I isolated neurofibrillary tangles of paired helical filaments (PHFs) from autopsied Alzheimer's disease (AD) brains and discovered that they were made up of a ~50–70 KDa protein on SDS‐polyacrylamide gels. Subsequently my team discovered that this PHF protein and the microtubule‐associated factor called tau were one and the same protein. However, we found that tau in neurofibrillary tangles/PHFs in AD brain was abnormally hyperphosphorylated, and unlike normal tau, which promoted the assembly of tubulin into microtubules, the AD‐hyperphosphorylated tau inhibited microtubule assembly. These discoveries of tau pathology in AD opened a new and a major area of research on tau and on the molecular pathology of this major cause of dementia in middle‐ and old‐age individuals. Tau pathology, which without fail is made up of the aggregated hyperphosphorylated state of the protein, is also the hallmark lesion of a family of around 20 related neurodegenerative diseases, called tauopathies. Currently, tau pathology is a major drug target for the treatment of AD and related tauopathies. Both active and passive tau immunization human clinical trials at various stages are underway. Initial results range from negative to partially promising. Future studies will reveal whether tau therapy alone or in combination with drugs targeting Aβ and/or neurodegeneration will be required to achieve the most effective treatment for AD and related disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, New York, USA.
- Phanes Biotech, Inc., Malvern, Pennsylvania, USA.
ORCID profiles: Khalid Iqbal
Funding
- NIA NIH HHS
- National Institutes of Health
- Office for People With Developmental Disabilities
Cite
APA
Iqbal, K. (2024). Tau and Alzheimer's disease: Past, present and future. Cytoskeleton. https://doi.org/10.1002/cm.21822
Vancouver
Iqbal K. Tau and Alzheimer's disease: Past, present and future. Cytoskeleton. 2024. doi:10.1002/cm.21822
BibTeX
@article{Iqbal2024,
author = {Iqbal, Khalid},
title = {Tau and Alzheimer's disease: Past, present and future},
journal = {Cytoskeleton},
year = {2024},
doi = {10.1002/cm.21822}
}
EUVIMED